Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 55

1.

In vitro susceptibility of urinary Escherichia coli isolates to first- and second-line empirically prescribed oral antimicrobials: CANWARD surveillance study results for Canadian outpatients, 2007-2016.

Karlowsky JA, Lagacé-Wiens PRS, Adam HJ, Baxter MR, Laing NM, Walkty AJ, Zhanel GG.

Int J Antimicrob Agents. 2019 Jul;54(1):62-68. doi: 10.1016/j.ijantimicag.2019.04.012. Epub 2019 Apr 26.

PMID:
31034938
2.

CHROMagar™ orientation urine culture medium produces matrix-assisted laser desorption ionization-time-of-flight mass spectrometry spectra misidentified as Mycoplasma arginini and Mycoplasma alkalescens.

Lagacé-Wiens PRS, Abbott AA, Karlowsky JA.

Diagn Microbiol Infect Dis. 2019 Jun;94(2):113-115. doi: 10.1016/j.diagmicrobio.2018.12.014. Epub 2019 Jan 2.

PMID:
30718158
3.

Cefiderocol: A Siderophore Cephalosporin with Activity Against Carbapenem-Resistant and Multidrug-Resistant Gram-Negative Bacilli.

Zhanel GG, Golden AR, Zelenitsky S, Wiebe K, Lawrence CK, Adam HJ, Idowu T, Domalaon R, Schweizer F, Zhanel MA, Lagacé-Wiens PRS, Walkty AJ, Noreddin A, Lynch Iii JP, Karlowsky JA.

Drugs. 2019 Feb;79(3):271-289. doi: 10.1007/s40265-019-1055-2. Review.

PMID:
30712199
4.

In Vitro Activity of Sulopenem, an Oral Penem, against Urinary Isolates of Escherichia coli.

Karlowsky JA, Adam HJ, Baxter MR, Denisuik AJ, Lagacé-Wiens PRS, Walkty AJ, Puttagunta S, Dunne MW, Zhanel GG.

Antimicrob Agents Chemother. 2018 Dec 21;63(1). pii: e01832-18. doi: 10.1128/AAC.01832-18. Print 2019 Jan.

PMID:
30397056
5.

Correction to: Imipenem-Relebactam and Meropenem-Vaborbactam: Two Novel Carbapenem-β-Lactamase Inhibitor Combinations.

Zhanel GG, Lawrence CK, Adam H, Schweizer F, Zelenitsky S, Zhanel M, Lagacé-Wiens PRS, Walkty A, Denisuik A, Golden A, Gin AS, Hoban DJ, Lynch JP 3rd, Karlowsky JA.

Drugs. 2018 May;78(7):787. doi: 10.1007/s40265-018-0910-x.

PMID:
29748749
6.

Imipenem-Relebactam and Meropenem-Vaborbactam: Two Novel Carbapenem-β-Lactamase Inhibitor Combinations.

Zhanel GG, Lawrence CK, Adam H, Schweizer F, Zelenitsky S, Zhanel M, Lagacé-Wiens PRS, Walkty A, Denisuik A, Golden A, Gin AS, Hoban DJ, Lynch JP 3rd, Karlowsky JA.

Drugs. 2018 Jan;78(1):65-98. doi: 10.1007/s40265-017-0851-9. Review. Erratum in: Drugs. 2018 May 10;:.

PMID:
29230684
7.

Antimicrobial susceptibility of clinical isolates of Neisseria gonorrhoeae to alternative antimicrobials with therapeutic potential.

Lagacé-Wiens PRS, Adam HJ, Laing NM, Baxter MR, Martin I, Mulvey MR, Karlowsky JA, Hoban DJ, Zhanel GG.

J Antimicrob Chemother. 2017 Aug 1;72(8):2273-2277. doi: 10.1093/jac/dkx147.

PMID:
28505331
8.

Solithromycin: A Novel Fluoroketolide for the Treatment of Community-Acquired Bacterial Pneumonia.

Zhanel GG, Hartel E, Adam H, Zelenitsky S, Zhanel MA, Golden A, Schweizer F, Gorityala B, Lagacé-Wiens PR, Walkty AJ, Gin AS, Hoban DJ, Lynch JP 3rd, Karlowsky JA.

Drugs. 2016 Dec;76(18):1737-1757. Review.

PMID:
27909995
9.

Review of Eravacycline, a Novel Fluorocycline Antibacterial Agent.

Zhanel GG, Cheung D, Adam H, Zelenitsky S, Golden A, Schweizer F, Gorityala B, Lagacé-Wiens PR, Walkty A, Gin AS, Hoban DJ, Karlowsky JA.

Drugs. 2016 Apr;76(5):567-88. doi: 10.1007/s40265-016-0545-8. Review.

PMID:
26863149
10.

Tedizolid: a novel oxazolidinone with potent activity against multidrug-resistant gram-positive pathogens.

Zhanel GG, Love R, Adam H, Golden A, Zelenitsky S, Schweizer F, Gorityala B, Lagacé-Wiens PR, Rubinstein E, Walkty A, Gin AS, Gilmour M, Hoban DJ, Lynch JP 3rd, Karlowsky JA.

Drugs. 2015 Feb;75(3):253-70. doi: 10.1007/s40265-015-0352-7. Review.

PMID:
25673021
11.

Evaluation of MRSASelect (™) chromogenic medium for the early detection of methicillin-resistant Staphylococcus aureus from blood cultures.

Manickam K, Walkty A, Lagacé-Wiens PR, Adam H, Swan B, McAdam B, Pieroni P, Alfa M, Karlowsky JA.

Can J Infect Dis Med Microbiol. 2013 Winter;24(4):e113-6.

12.

Ceftolozane/tazobactam: a novel cephalosporin/β-lactamase inhibitor combination with activity against multidrug-resistant gram-negative bacilli.

Zhanel GG, Chung P, Adam H, Zelenitsky S, Denisuik A, Schweizer F, Lagacé-Wiens PR, Rubinstein E, Gin AS, Walkty A, Hoban DJ, Lynch JP 3rd, Karlowsky JA.

Drugs. 2014 Jan;74(1):31-51. doi: 10.1007/s40265-013-0168-2. Review.

PMID:
24352909
13.

In Vitro activity of fosfomycin against Escherichia coli isolated from patients with urinary tract infections in Canada as part of the CANWARD surveillance study.

Karlowsky JA, Denisuik AJ, Lagacé-Wiens PR, Adam HJ, Baxter MR, Hoban DJ, Zhanel GG.

Antimicrob Agents Chemother. 2014;58(2):1252-6. doi: 10.1128/AAC.02399-13. Epub 2013 Dec 9.

14.

In vitro activity of ceftaroline-avibactam against gram-negative and gram-positive pathogens isolated from patients in Canadian hospitals from 2010 to 2012: results from the CANWARD surveillance study.

Karlowsky JA, Adam HJ, Baxter MR, Lagacé-Wiens PR, Walkty AJ, Hoban DJ, Zhanel GG.

Antimicrob Agents Chemother. 2013 Nov;57(11):5600-11. doi: 10.1128/AAC.01485-13. Epub 2013 Aug 26.

15.

Successful treatment of pulmonary blastomycosis with continuously infused amphotericin B deoxycholate after failure with liposomal amphotericin B.

Ariano RE, Mitchelmore BR, Lagacé-Wiens PR, Zelenitsky SA.

Ann Pharmacother. 2013 Jun;47(6):e26. doi: 10.1345/aph.1R703. Epub 2013 May 14.

PMID:
23673538
16.

Antimicrobial susceptibility of 22746 pathogens from Canadian hospitals: results of the CANWARD 2007-11 study.

Zhanel GG, Adam HJ, Baxter MR, Fuller J, Nichol KA, Denisuik AJ, Lagacé-Wiens PR, Walkty A, Karlowsky JA, Schweizer F, Hoban DJ; Canadian Antimicrobial Resistance Alliance.

J Antimicrob Chemother. 2013 May;68 Suppl 1:i7-22. doi: 10.1093/jac/dkt022.

PMID:
23587781
17.

Molecular epidemiology of extended-spectrum β-lactamase-, AmpC β-lactamase- and carbapenemase-producing Escherichia coli and Klebsiella pneumoniae isolated from Canadian hospitals over a 5 year period: CANWARD 2007-11.

Denisuik AJ, Lagacé-Wiens PR, Pitout JD, Mulvey MR, Simner PJ, Tailor F, Karlowsky JA, Hoban DJ, Adam HJ, Zhanel GG; Canadian Antimicrobial Resistance Alliance.

J Antimicrob Chemother. 2013 May;68 Suppl 1:i57-65. doi: 10.1093/jac/dkt027.

PMID:
23587779
18.

Changing epidemiology of methicillin-resistant Staphylococcus aureus in Canada.

Nichol KA, Adam HJ, Roscoe DL, Golding GR, Lagacé-Wiens PR, Hoban DJ, Zhanel GG; Canadian Antimicrobial Resistance Alliance.

J Antimicrob Chemother. 2013 May;68 Suppl 1:i47-55. doi: 10.1093/jac/dkt026.

PMID:
23587778
19.

Changes in fluoroquinolone resistance over 5 years (CANWARD 2007-11) in bacterial pathogens isolated in Canadian hospitals.

Karlowsky JA, Adam HJ, Desjardins M, Lagacé-Wiens PR, Hoban DJ, Zhanel GG; Canadian Antimicrobial Resistance Alliance.

J Antimicrob Chemother. 2013 May;68 Suppl 1:i39-46. doi: 10.1093/jac/dkt025.

PMID:
23587777
20.

Comparison of pathogens and their antimicrobial resistance patterns in paediatric, adult and elderly patients in Canadian hospitals.

Adam HJ, Baxter MR, Davidson RJ, Rubinstein E, Fanella S, Karlowsky JA, Lagacé-Wiens PR, Hoban DJ, Zhanel GG; Canadian Antimicrobial Resistance Alliance (CARA).

J Antimicrob Chemother. 2013 May;68 Suppl 1:i31-7. doi: 10.1093/jac/dkt024.

PMID:
23587776
21.

Trends in antibiotic resistance over time among pathogens from Canadian hospitals: results of the CANWARD study 2007-11.

Lagacé-Wiens PR, Adam HJ, Low DE, Blondeau JM, Baxter MR, Denisuik AJ, Nichol KA, Walkty A, Karlowsky JA, Mulvey MR, Hoban DJ, Zhanel GG; Canadian Antimicrobial Resistance Alliance.

J Antimicrob Chemother. 2013 May;68 Suppl 1:i23-9. doi: 10.1093/jac/dkt023.

PMID:
23587775
22.

Pharmacokinetic and pharmacodynamics evaluation of ceftobiprole medocaril for the treatment of hospital-acquired pneumonia.

Lagacé-Wiens PR, Rubinstein E.

Expert Opin Drug Metab Toxicol. 2013 Jun;9(6):789-99. doi: 10.1517/17425255.2013.788150. Epub 2013 Apr 17. Review.

PMID:
23590397
23.

Ceftazidime-avibactam: a novel cephalosporin/β-lactamase inhibitor combination.

Zhanel GG, Lawson CD, Adam H, Schweizer F, Zelenitsky S, Lagacé-Wiens PR, Denisuik A, Rubinstein E, Gin AS, Hoban DJ, Lynch JP 3rd, Karlowsky JA.

Drugs. 2013 Feb;73(2):159-77. doi: 10.1007/s40265-013-0013-7. Review.

PMID:
23371303
24.

CHROMagar Orientation medium reduces urine culture workload.

Manickam K, Karlowsky JA, Adam H, Lagacé-Wiens PR, Rendina A, Pang P, Murray BL, Alfa MJ.

J Clin Microbiol. 2013 Apr;51(4):1179-83. doi: 10.1128/JCM.02877-12. Epub 2013 Jan 30.

25.

Evaluation of an algorithmic approach in comparison with the Illumigene assay for laboratory diagnosis of Clostridium difficile infection.

Walkty A, Lagacé-Wiens PR, Manickam K, Adam H, Pieroni P, Hoban D, Karlowsky JA, Alfa M.

J Clin Microbiol. 2013 Apr;51(4):1152-7. doi: 10.1128/JCM.03203-12. Epub 2013 Jan 30.

26.

Identification of blood culture isolates directly from positive blood cultures by use of matrix-assisted laser desorption ionization-time of flight mass spectrometry and a commercial extraction system: analysis of performance, cost, and turnaround time.

Lagacé-Wiens PR, Adam HJ, Karlowsky JA, Nichol KA, Pang PF, Guenther J, Webb AA, Miller C, Alfa MJ.

J Clin Microbiol. 2012 Oct;50(10):3324-8. doi: 10.1128/JCM.01479-12. Epub 2012 Aug 8.

27.

Re-evaluation of rejection criteria for endotracheal tube (ETT) specimens from adult patients.

Walkty A, Lagacé-Wiens PR, Manickam K, Adam H, Pieroni P, Alfa M, Karlowsky JA.

J Med Microbiol. 2012 Sep;61(Pt 9):1306-10. doi: 10.1099/jmm.0.042333-0. Epub 2012 Jun 14.

PMID:
22700550
28.

Emergence of fluoroquinolone resistance in Neisseria gonorrhoeae isolates from four clinics in three regions of Kenya.

Lagace-Wiens PR, Duncan S, Kimani J, Thiong'o A, Shafi J, McClelland S, Sanders EJ, Zhanel G, Muraguri N, Mehta SD.

Sex Transm Dis. 2012 May;39(5):332-4. doi: 10.1097/OLQ.0b013e318248a85f.

29.

Change in antimicrobial susceptibility of Escherichia coli urinary tract isolates at a single institution over a period of 10 years.

Walkty A, Lagacé-Wiens PR, Karlowsky JA, Hoban DJ, Manickam K, Adam H, Pieroni P, Alfa M.

Can J Microbiol. 2012 Mar;58(3):345-9. doi: 10.1139/w2012-001. Epub 2012 Feb 27.

PMID:
22369590
30.

Fluoroquinolone resistance in Escherichia coli isolated from patients attending Canadian hospitals is associated with the ST131 clone.

Simner PJ, Hoban DJ, Lagacé-Wiens PR, Zhanel GG, Karlowsky JA.

Diagn Microbiol Infect Dis. 2011 Nov;71(3):323-4. doi: 10.1016/j.diagmicrobio.2011.07.016. Epub 2011 Sep 1. No abstract available.

PMID:
21889284
31.

Antimicrobial resistance in urinary tract pathogens in Canada from 2007 to 2009: CANWARD surveillance study.

Karlowsky JA, Lagacé-Wiens PR, Simner PJ, DeCorby MR, Adam HJ, Walkty A, Hoban DJ, Zhanel GG.

Antimicrob Agents Chemother. 2011 Jul;55(7):3169-75. doi: 10.1128/AAC.00066-11. Epub 2011 May 2.

32.

In vitro activity of ceftazidime combined with NXL104 versus Pseudomonas aeruginosa isolates obtained from patients in Canadian hospitals (CANWARD 2009 study).

Walkty A, DeCorby M, Lagacé-Wiens PR, Karlowsky JA, Hoban DJ, Zhanel GG.

Antimicrob Agents Chemother. 2011 Jun;55(6):2992-4. doi: 10.1128/AAC.01696-10. Epub 2011 Mar 21.

33.

In vitro activity of ceftaroline against gram-positive and gram-negative pathogens isolated from patients in Canadian hospitals in 2009.

Karlowsky JA, Adam HJ, Decorby MR, Lagacé-Wiens PR, Hoban DJ, Zhanel GG.

Antimicrob Agents Chemother. 2011 Jun;55(6):2837-46. doi: 10.1128/AAC.01787-10. Epub 2011 Mar 14.

34.

Activity of NXL104 in combination with beta-lactams against genetically characterized Escherichia coli and Klebsiella pneumoniae isolates producing class A extended-spectrum beta-lactamases and class C beta-lactamases.

Lagacé-Wiens PR, Tailor F, Simner P, DeCorby M, Karlowsky JA, Walkty A, Hoban DJ, Zhanel GG.

Antimicrob Agents Chemother. 2011 May;55(5):2434-7. doi: 10.1128/AAC.01722-10. Epub 2011 Feb 28.

35.

Prevalence and characterization of extended-spectrum β-lactamase- and AmpC β-lactamase-producing Escherichia coli: results of the CANWARD 2007-2009 study.

Simner PJ, Zhanel GG, Pitout J, Tailor F, McCracken M, Mulvey MR, Lagacé-Wiens PR, Adam HJ, Hoban DJ; Canadian Antimicrobial Resistance Alliance (CARA).

Diagn Microbiol Infect Dis. 2011 Mar;69(3):326-34. doi: 10.1016/j.diagmicrobio.2010.10.029.

PMID:
21353961
36.

Comparison of community-associated and health care-associated methicillin-resistant Staphylococcus aureus in Canada: results of the CANWARD 2007-2009 study.

Nichol KA, Adam HJ, Hussain Z, Mulvey MR, McCracken M, Mataseje LF, Thompson K, Kost S, Lagacé-Wiens PR, Hoban DJ, Zhanel GG; Canadian Antimicrobial Resistance Alliance (CARA).

Diagn Microbiol Infect Dis. 2011 Mar;69(3):320-5. doi: 10.1016/j.diagmicrobio.2010.10.028.

PMID:
21353960
37.

Analysis of 3789 in- and outpatient Escherichia coli isolates from across Canada--results of the CANWARD 2007-2009 study.

Lagacé-Wiens PR, Simner PJ, Forward KR, Tailor F, Adam HJ, Decorby M, Karlowsky J, Hoban DJ, Zhanel GG; Canadian Antimicrobial Resistance Alliance (CARA).

Diagn Microbiol Infect Dis. 2011 Mar;69(3):314-9. doi: 10.1016/j.diagmicrobio.2010.10.027.

PMID:
21353959
38.

New lipoglycopeptides: a comparative review of dalbavancin, oritavancin and telavancin.

Zhanel GG, Calic D, Schweizer F, Zelenitsky S, Adam H, Lagacé-Wiens PR, Rubinstein E, Gin AS, Hoban DJ, Karlowsky JA.

Drugs. 2010 May 7;70(7):859-86. doi: 10.2165/11534440-000000000-00000. Review. Erratum in: Drugs. 2011 Mar 26;71(5):526.

PMID:
20426497
39.

First description of an extended-spectrum-beta-lactamase-producing multidrug-resistant Escherichia fergusonii strain in a patient with cystitis.

Lagacé-Wiens PR, Baudry PJ, Pang P, Hammond G.

J Clin Microbiol. 2010 Jun;48(6):2301-2. doi: 10.1128/JCM.00364-10. Epub 2010 Apr 21.

40.

Influenza epidemiology--past, present, and future.

Lagacé-Wiens PR, Rubinstein E, Gumel A.

Crit Care Med. 2010 Apr;38(4 Suppl):e1-9. doi: 10.1097/CCM.0b013e3181cbaf34. Review.

PMID:
20029350
41.

Annual macrolide prescription rates and the emergence of macrolide resistance among Streptococcus pneumoniae in Canada from 1995 to 2005.

Karlowsky JA, Lagacé-Wiens PR, Low DE, Zhanel GG.

Int J Antimicrob Agents. 2009 Oct;34(4):375-9. doi: 10.1016/j.ijantimicag.2009.05.008. Epub 2009 Jun 27.

PMID:
19560902
42.

Ceftaroline: a novel broad-spectrum cephalosporin with activity against meticillin-resistant Staphylococcus aureus.

Zhanel GG, Sniezek G, Schweizer F, Zelenitsky S, Lagacé-Wiens PR, Rubinstein E, Gin AS, Hoban DJ, Karlowsky JA.

Drugs. 2009;69(7):809-31. doi: 10.2165/00003495-200969070-00003. Review.

PMID:
19441869
43.

Differences in antimicrobial susceptibility in Escherichia coli from Canadian intensive care units based on regional and demographic variables.

Lagacé-Wiens PR, Decorby MR, Baudry PJ, Hoban DJ, Karlowsky JA, Zhanel GG; CAN-ICU study group.

Can J Infect Dis Med Microbiol. 2008 Jul;19(4):282-6.

45.

The diabetic foot clinic: not a significant source for acquisition of methicillin-resistant Staphylococcus aureus.

Lagacé-Wiens PR, Ormiston D, Nicolle LE, Hilderman T, Embil J.

Am J Infect Control. 2009 Sep;37(7):587-9. doi: 10.1016/j.ajic.2008.11.006. Epub 2009 Feb 25.

PMID:
19243857
46.

ESBL genotypes in fluoroquinolone-resistant and fluoroquinolone-susceptible ESBL-producing Escherichia coli urinary isolates in Manitoba.

Lagacé-Wiens PR, Nichol KA, Nicolle LE, Decorby MR, McCracken M, Alfa MJ, Mulvey MR, Zhanel GG.

Can J Infect Dis Med Microbiol. 2007 Mar;18(2):133-7.

47.

Human ophthalmomyiasis interna caused by Hypoderma tarandi, Northern Canada.

Lagacé-Wiens PR, Dookeran R, Skinner S, Leicht R, Colwell DD, Galloway TD.

Emerg Infect Dis. 2008 Jan;14(1):64-6. doi: 10.3201/eid1401.070163. Review.

48.

Dalbavancin and telavancin: novel lipoglycopeptides for the treatment of Gram-positive infections.

Zhanel GG, Trapp S, Gin AS, DeCorby M, Lagacé-Wiens PR, Rubinstein E, Hoban DJ, Karlowsky JA.

Expert Rev Anti Infect Ther. 2008 Feb;6(1):67-81. doi: 10.1586/14787210.6.1.67. Review.

PMID:
18251665
49.

Reductions in workload and reporting time by use of methicillin-resistant Staphylococcus aureus screening with MRSASelect medium compared to mannitol-salt medium supplemented with oxacillin.

Lagacé-Wiens PR, Alfa MJ, Manickam K, Harding GK.

J Clin Microbiol. 2008 Apr;46(4):1174-7. doi: 10.1128/JCM.01253-07. Epub 2008 Jan 30.

50.

Gardnerella vaginalis bacteremia in a previously healthy man: case report and characterization of the isolate.

Lagacé-Wiens PR, Ng B, Reimer A, Burdz T, Wiebe D, Bernard K.

J Clin Microbiol. 2008 Feb;46(2):804-6. Epub 2007 Dec 5.

Supplemental Content

Loading ...
Support Center